Biomerieux SA (BIM) - Total Assets
Based on the latest financial reports, Biomerieux SA (BIM) holds total assets worth €5.57 Billion EUR (≈ $6.52 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Biomerieux SA debt service capacity to assess how comfortably operating cash covers total debt obligations.
Biomerieux SA - Total Assets Trend (2005–2025)
This chart illustrates how Biomerieux SA's total assets have evolved over time, based on quarterly financial data. See Biomerieux SA (BIM) net assets for net asset value and shareholders' equity analysis.
Biomerieux SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Biomerieux SA's total assets of €5.57 Billion consist of 45.6% current assets and 54.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €312.10 Million | 10.2% |
| Accounts Receivable | €1.01 Billion | 18.1% |
| Inventory | €959.70 Million | 17.2% |
| Property, Plant & Equipment | €1.66 Billion | 29.7% |
| Intangible Assets | €401.50 Million | 7.2% |
| Goodwill | €727.80 Million | 13.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Biomerieux SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomerieux SA's current assets represent 45.6% of total assets in 2025, a decrease from 52.7% in 2005.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, up from 2.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 9.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.7% of total assets.
Biomerieux SA Competitors by Total Assets
Key competitors of Biomerieux SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Biomerieux SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 2.20 | 1.80 |
| Quick Ratio | 1.48 | 1.29 | 1.19 |
| Cash Ratio | 0.29 | 0.21 | 0.00 |
| Working Capital | €1.48 Billion | €1.37 Billion | €737.80 Million |
Biomerieux SA - Advanced Valuation Insights
This section examines the relationship between Biomerieux SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.04 |
| Latest Market Cap to Assets Ratio | 1.52 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | €5.57 Billion |
| Market Capitalization | $8.48 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Biomerieux SA's assets above their book value (1.52x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Biomerieux SA's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Biomerieux SA (2005–2025)
The table below shows the annual total assets of Biomerieux SA from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €5.57 Billion ≈ $6.52 Billion |
-3.38% |
| 2024-12-31 | €5.77 Billion ≈ $6.75 Billion |
+9.71% |
| 2023-12-31 | €5.26 Billion ≈ $6.15 Billion |
+1.40% |
| 2022-12-31 | €5.19 Billion ≈ $6.06 Billion |
+12.63% |
| 2021-12-31 | €4.61 Billion ≈ $5.38 Billion |
+17.24% |
| 2020-12-31 | €3.93 Billion ≈ $4.59 Billion |
+3.86% |
| 2019-12-31 | €3.78 Billion ≈ $4.42 Billion |
+7.92% |
| 2018-12-31 | €3.50 Billion ≈ $4.10 Billion |
+17.20% |
| 2017-12-31 | €2.99 Billion ≈ $3.50 Billion |
-1.28% |
| 2016-12-31 | €3.03 Billion ≈ $3.54 Billion |
+9.20% |
| 2015-12-31 | €2.77 Billion ≈ $3.24 Billion |
+7.48% |
| 2014-12-31 | €2.58 Billion ≈ $3.02 Billion |
+17.48% |
| 2013-12-31 | €2.20 Billion ≈ $2.57 Billion |
+19.82% |
| 2012-12-31 | €1.83 Billion ≈ $2.14 Billion |
+4.03% |
| 2011-12-31 | €1.76 Billion ≈ $2.06 Billion |
+21.64% |
| 2010-12-31 | €1.45 Billion ≈ $1.69 Billion |
+15.00% |
| 2009-12-31 | €1.26 Billion ≈ $1.47 Billion |
+5.93% |
| 2008-12-31 | €1.19 Billion ≈ $1.39 Billion |
+19.11% |
| 2007-12-31 | €998.40 Million ≈ $1.17 Billion |
+6.26% |
| 2006-12-31 | €939.60 Million ≈ $1.10 Billion |
+3.70% |
| 2005-12-31 | €906.10 Million ≈ $1.06 Billion |
-- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more